Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
Loomba, Rohit , Sirlin, Claude B. , Ang, Brandon, Bettencourt, Ricki , Jain, Rashmi , Salotti, Joanie, Soaft, Linda, Hooker, Jonathan , Bhatt, Archana, Hernandez, Laura, Nguyen, Phirum, Noureddin, Mazen , Haufe, William, Hooker, Catherine A., Yin, Meng , Valasek, Mark A. , Brenner, David A. , Richards, Lisa , Kono, Yuko , Ehman, Richard L. , Lin, Grace , Sirlin, Claude B. , Loomba, Rohit , Yin, Meng

Mayo Clinic

Hepatology | December 9, 2014 | Volume: 61 | Issue: 4 | Pages: 1239-1250

10.1002/hep.27647 | PMID 25482832 Get It

Ezetimibe inhibits intestinal cholesterol absorption and lowers low‐density lipoprotein cholesterol. Uncontrolled studies have suggested that it reduces liver fat as estimated by ultrasound in nonalcoholic steatohepatitis (NASH). Therefore, we aimed to examine the efficacy of ezetimibe versus placebo in reducing liver fat by the magnetic resonance imaging‐derived proton density‐fat fraction (MRI‐PDFF) and liver histology in patients with biopsy‐proven NASH. In this randomized, double‐blind, placebo‐controlled trial, 50 patients with biopsy‐proven NASH were randomized to either ezetimibe 10 mg orally daily or placebo for 24 weeks. The primary outcome was a change in liver fat as measured by MRI‐PDFF in colocalized regions of interest within each of the nine liver segments. Novel assessment by two‐dimensional and three‐dimensional magnetic resonance elastography was also performed. Ezetimibe was not significantly better than placebo at reducing liver fat as measured by MRI‐PDFF (mean difference between the ezetimibe and placebo arms ‐1.3%, P = 0.4). Compared to baseline, however, end‐of‐treatment MRI‐PDFF was significantly lower in the ezetimibe arm (15%‐11.6%, P < 0.016) but not in the placebo arm (18.5%‐16.4%, P = 0.15). There were no significant differences in histologic response rates, serum alanine aminotransferase and aspartate aminotransferase levels, or longitudinal changes in two‐dimensional and three‐dimensional magnetic resonance elastography‐derived liver stiffness between the ezetimibe and placebo arms. Compared to histologic nonresponders (25/35), histologic responders (10/35) had a significantly greater reduction in MRI‐PDFF (‐4.35 ± 4.9% versus ‐0.30 ± 4.1%, P < 0.019). Conclusions : Ezetimibe did not significantly reduce liver fat in NASH. This trial demonstrates the application of colocalization of MRI‐PDFF‐derived fat maps and magnetic resonance elastography‐derived stiffness maps of the liver before and after treatment to noninvasively assess treatment response in NASH. (H epatology 2015;61:1239–1250)
Home Discharge as a Performance Metric for Surgery
Hyder, Joseph A. , Hirschberg, Ronald E., Nguyen, Louis L.

Mayo Clinic

JAMA Surgery | December 4, 2014 | Volume: 150 | Issue: 2 | Pages: 96

10.1001/jamasurg.2014.1725 | PMID 25472699 Get It

Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma
Koh, Mei Yee , Nguyen, Vuvi, Lemos, Robert, Darnay, Bryant G., Kiriakova, Galina M., Abdelmelek, Mena, Ho, Thai H. , Monzon, Federico A. , Powis, Garth , Karam, Jose Antonio , Jonasch, Eric W. , Ho, Thai , Koh, Mei Yee

Mayo Clinic

Cancer Research | November 24, 2014 | Volume: 75 | Issue: 2 | Pages: 316-329

10.1158/0008-5472.can-13-2190 | PMID 25421578 Get It

Abstract Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1α E3 ligase hypoxia-associated factor (HAF) complexes with HIF2α at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1α degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. Cancer Res; 75(2); 316–29. ©2014 AACR.
Synchronous hepatic and splenic inflammatory pseudotumour‐like follicular dendritic cell sarcomas
Roarke, Michael C., Yang, Ming , Nguyen, Ba D.

Mayo Clinic

Liver International | November 18, 2014 | Volume: 35 | Issue: 7 | Pages: 1917-1917

10.1111/liv.12738 | PMID 25404171 Get It

Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database
Wang, Elyn H. , Yu, James B. , Gross, Cary P. , Smaldone, Marc C. , Shah, Nilay D., Nguyen, Paul L. , Sun, Maxine , Han, Leona C., Kim, Simon P. , Trinh, Quoc‐Dien , Yu, James B

Mayo Clinic

Journal of Urology | September 19, 2014 | Volume: 193 | Issue: 3 | Pages: 820-825

10.1016/j.juro.2014.09.019 | PMID 25242393 Get It

Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms
Jevremović, Dragan , Timm, Michael, Reichard, Kaaren K. , Morice, William G. , Hanson, Curtis A. , Viswanatha, David S., Howard, Matthew T., Nguyen, Phuong L., Timm, Michael M, Morice, William George , Jevremovic, Dragan

Mayo Clinic

American Journal of Clinical Pathology | August 14, 2014 | Volume: 142 | Issue: 3 | Pages: 292-298

10.1309/ajcp73qsllydegxk | PMID 25125617 Get It

Abstract Objectives: Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluation of myeloid malignancies, especially in the myelodysplastic syndromes. However, its use has been limited due to complexity and cost restraints. The goal of this study is to attempt a simpler approach to flow cytometry immunophenotyping in myeloid neoplasms. Methods: We analyzed bone marrow specimens of 45 selected patients and an additional 99 consecutive random patients using a limited antibody panel. Results: Normal CD34-positive blasts show a characteristic pattern of CD13/HLA-DR expression, with three readily identifiable subpopulations. In contrast, myeloid neoplasms frequently show loss of this heterogeneity. Conclusions: Analysis of a limited antibody panel with a focus on CD13/HLA-DR expression provides relatively high specificity and sensitivity for the detection of myeloid neoplasms.